Information About Vaxzevria^▼ COVID-19 Vaccine (ChAdOx1-S [recombinant])

Disclaimer: The information on this page is intended for Vaccine Recipients only.

A Conditional Marketing Authorisation has been granted in Great Britain for the product Vaxzevria for active immunisation of individuals aged 18 years and older for the prevention of coronavirus disease 2019 (COVID-19).

As with any new medicine in the UK this product will be closely monitored to allow quick identification of new safety information. You can help by reporting any side effects you may get.

 

Conditional Marketing approval for GB Healthcare Professionals

You can visit the GOV.UK site for more information on Vaxzevria. This link will take you to another website. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.

 

Reporting of side effects

If you are concerned about a side-effect, it can be reported directly via the Coronavirus Yellow Card reporting site https://coronavirus-yellowcard.mhra.gov.uk/, or search for MHRA Yellow Card in the Google Play or Apple App Store and include the vaccine brand and batch/lot number if available.

This link will take you to another website. AstraZeneca provides this link as a service to website visitors. AstraZeneca is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.